Serial biotech entrepreneur and co-founder of several biotech companies including Symphogen A/S, Prosidion Ltd in the UK and Santaris Pharma A/S. Background spans academia, large pharma as well as biotech with positions held in R&D, Business & Corporate Development as well as Executive Management. International track record in R&D productivity & deal making including execution of high impact license agreements as well as significant M&A transactions. Former managing director of OSI Pharmaceutical’s venture arm in Switzerland which has invested in several biotech companies including Danish Epitherapeutics A/S. Previously held positions at OSI Pharmaceuticals Inc., Prosidion Ltd., Novo Nordisk and has served as member of the Board of Directors for Symphogen, Prosidion Ltd, OSI Pharmaceuticals UK Limited, OSI Investment Holding GmbH & OSI Investment Management GmbH and for Display Biotech Systems. Dr Lundemose is a Medical Doctor from University of Aarhus, and holds Ph.D. degree in Molecular Microbiology and a degree as Doctor of Medical Science (Dr. med.), both from University of Aarhus.

 Ophthalmology